374777-77-2

Basic information

• Product Name: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester
• Synonyms: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester;(2S)-dimethyl 2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioate
• CAS NO: 374777-77-2
• Molecular Formula: C₂₅H₂₇N₇O₅
• Molecular Weight: 505.52578
• Mol File: 374777-77-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(374777-77-2)
• EPA Substance Registry System: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(374777-77-2)

Safety Data

• Hazardous Substances Data: 374777-77-2(Hazardous Substances Data)

Usage

General Description

L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, 1,5-dimethyl ester is a chemical compound that is derived from glutamic acid and pteridines. It is an ester formed by the reaction of 1,5-dimethyl alcohol with the benzoyl group of this compound. This chemical has potential pharmaceutical applications as it contains a pteridine structure, which is a key component in various biological processes. The presence of the benzoyl group also suggests possible medicinal properties due to its known pharmacological effects. Overall, this compound has the potential to be utilized in pharmaceutical research and drug development due to its unique structure and properties.

Upstream product

• 23150-65-4 L-glutamic dimethyl ester hydrochloride 
• 146464-93-9 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 
• 1548618-47-8 10-propargyl-10-carbomethoxy-4-deoxy-4-amino-10-deazapteroic acid methyl ester hydrobromide salt 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 1445586-50-4 10-propargyl-10-carboxy-4-deoxy-4-amino-10-deazapteroic acid sodium salt 
• 146464-90-6 α-propargylhomoterephthalic acid dimethyl ester 
• 146464-92-8 4-(2-carboxy-1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 
• 146464-91-7 methyl-4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate 
• 52787-14-1 methyl 4-(2-methoxy-2-oxoethyl)benzoate 

Downstream Products

• 1320211-82-2 C₂₅H₂₇N₇O₅ 
• 1320211-79-7 C₂₅H₂₇N₇O₅ 
• 146464-95-1 pralatrexate 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE

An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.

PROCESS FOR PREPARATION OF AN ANTIFOLATE AGENT

The specification relates to a process for preparation of an antifolate compound of formula 7, such as Pralatrexate. Also, disclosed are intermediates and processes for preparation of intermediates useful in the preparation of the antifolate compound. The substituents Y, Z, R, R1 and R2 are as described herein. The processes and intermediates can provide an alternate route to the synthesis of the antifolate compound. Further, the processes can help to avoid distillation or evaporation of high boiling point solvents, chromatographic purification and use of hazardous combination of solvents; and can also provide a product having high purity, all of which are desirable for synthesis on a large scale.

Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin

T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2 per dose.